| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1023515930 |
| P356 | DOI | 10.1186/S13019-016-0519-7 |
| P932 | PMC publication ID | 4972954 |
| P698 | PubMed publication ID | 27488025 |
| P50 | author | A Kornberger | Q85674706 |
| P2093 | author name string | U A Stock | |
| B Luchting | |||
| A Beiras-Fernandez | |||
| F Weis | |||
| M Weis | |||
| F Kur | |||
| P2860 | cites work | Antimicrobial resistance in gram-positive bacteria | Q79823680 |
| Sternal surgical-site infection following coronary artery bypass graft: prevalence, microbiology, and complications during a 42-month period | Q80308327 | ||
| Daptomycin | Q80608154 | ||
| High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study | Q84954829 | ||
| Complications of cardiac implants: handling device infections | Q26865664 | ||
| Efficacy and safety of daptomycin for the treatment of infectious disease: a meta-analysis based on randomized controlled trials | Q27000445 | ||
| Management practices and major infections after cardiac surgery. | Q30371753 | ||
| Acute kidney injury associated with cardiac surgery | Q30444258 | ||
| Treatment options for vancomycin-resistant enterococcal infections | Q33340899 | ||
| Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America | Q33688646 | ||
| High-dose daptomycin and fosfomycin treatment of a patient with endocarditis caused by daptomycin-nonsusceptible Staphylococcus aureus: case report | Q33911941 | ||
| Development of daptomycin for gram-positive infections | Q33920377 | ||
| Center-level variation in infection rates after coronary artery bypass grafting | Q34033646 | ||
| Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children | Q34157657 | ||
| Vancomycin-resistant Enterococcus faecium: catheter colonization, esp gene, and decreased susceptibility to antibiotics in biofilm | Q34228237 | ||
| Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus | Q34558111 | ||
| Safety and efficacy of high-dose daptomycin as salvage therapy for severe gram-positive bacterial sepsis in hospitalized adult patients | Q34573702 | ||
| Clinical experience with daptomycin in Europe: the first 2.5 years | Q34681219 | ||
| Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens | Q35026595 | ||
| Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers | Q35091557 | ||
| A review of daptomycin for injection (Cubicin) in the treatment of complicated skin and skin structure infections | Q35166807 | ||
| Treatment of gram-positive deep sternal wound infections in cardiac surgery--experiences with daptomycin. | Q35248216 | ||
| Nonvalvular cardiovascular device-related infections | Q35564150 | ||
| High-dose daptomycin therapy for staphylococcal endocarditis and when to apply it. | Q35848781 | ||
| Linezolid Compared with Eperezolid, Vancomycin, and Gentamicin in an In Vitro Model of Antimicrobial Lock Therapy for Staphylococcus epidermidis Central Venous Catheter-Related Biofilm Infections | Q36047645 | ||
| Daptomycin as supportive treatment option in patients developing mediastinitis after open cardiac surgery | Q36361545 | ||
| Pacemaker-induced Staphylococcus aureus mitral valve acute bacterial endocarditis complicated by persistent bacteremia from a coronary stent: Cure with prolonged/high-dose daptomycin without toxicity | Q36478933 | ||
| Epidemiology and outcome of major postoperative infections following cardiac surgery: risk factors and impact of pathogen type | Q36503755 | ||
| Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections | Q36777821 | ||
| Deep sternal wound infection after cardiac surgery | Q36874100 | ||
| Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections | Q36916071 | ||
| Daptomycin use in patients with osteomyelitis: a preliminary report from the EU-CORE(SM) database | Q36929393 | ||
| Daptomycin-induced acute renal and hepatic toxicity without rhabdomyolysis | Q37125518 | ||
| Outpatient parenteral antibiotic therapy with daptomycin: insights from a patient registry | Q37134271 | ||
| A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis | Q37286911 | ||
| High-dose, short-interval daptomycin regimen was safe and well tolerated in three patients with chronic renal failure | Q37291084 | ||
| Clinical experience with daptomycin for outpatient parenteral antibiotic therapy | Q37895066 | ||
| The potential role of newer gram-positive antibiotics in the setting of osteomyelitis of adults | Q38084726 | ||
| Corynebacterium striatum: an emerging nosocomial drug-resistant endocardial pathogen | Q38154904 | ||
| Eradication of a chronic wound and driveline infection after redo-LVAD implantation | Q38588212 | ||
| Clinical predictors of major infections after cardiac surgery | Q40389576 | ||
| Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center | Q40416541 | ||
| Midterm results after treatment of gram-positive deep sternal wound infections with daptomycin for cardiac surgery patients | Q41084866 | ||
| Daptomycin rapidly penetrates a Staphylococcus epidermidis biofilm | Q41876061 | ||
| Pacemaker endocarditis caused by Propionibacterium acnes in an adult patient with Ebstein's anomaly: a report of a rare case. | Q42205170 | ||
| Mediastinitis after more than 10,000 cardiac surgical procedures | Q42601645 | ||
| Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm | Q42845932 | ||
| Multidrug-resistant gram-positive infections in patients with ventricular assist devices: the role of daptomycin | Q43283956 | ||
| High-dose daptomycin for cardiac implantable electronic device-related infective endocarditis | Q43443557 | ||
| Use of daptomycin to treat drug-resistant Gram-positive bone and joint infections | Q43532746 | ||
| Safety and efficacy of daptomycin in the treatment of osteomyelitis: results from the CORE Registry | Q43997965 | ||
| Daptomycin for the treatment of infective endocarditis: results from a European registry | Q44271960 | ||
| Post-operative deep sternal wound infections: making an early microbiological diagnosis | Q44294753 | ||
| MRSA pneumonia: better outcome through continuous infusion of vancomycin? | Q44616080 | ||
| Methicillin-resistant Staphylococcus aureus (MRSA) mitral valve acute bacterial endocarditis (ABE) in a patient with Job's syndrome (hyperimmunoglobulin E syndrome) successfully treated with linezolid and high-dose daptomycin | Q44675479 | ||
| Reduction in incidence of deep sternal wound infections: random or real? | Q44881715 | ||
| Risk and outcome analysis of renal replacement therapies in patients after cardiac surgery with pre-operatively normal renal function. | Q46005759 | ||
| Neutropenia associated with prolonged daptomycin use. | Q46024308 | ||
| Pharmacokinetics and safety of multiple intravenous doses of daptomycin in a Taiwanese adult population | Q46162350 | ||
| Antibacterial activity of linezolid and vancomycin in an in vitro pharmacodynamic model of gram-positive catheter-related bacteraemia | Q46425775 | ||
| Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact | Q46494181 | ||
| Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia | Q46620650 | ||
| Update of the in vitro activity of daptomycin tested against 6710 Gram-positive cocci isolated in North America (2006). | Q46722690 | ||
| E. faecalis vancomycin-sensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin | Q46898377 | ||
| Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia | Q46902038 | ||
| Daptomycin in the treatment of patients with infective endocarditis: experience from a registry | Q46974830 | ||
| Cardiovascular implantable electronic device endocarditis treated with daptomycin with or without transvenous removal. | Q47995896 | ||
| Acute kidney injury after cardiac surgery: focus on modifiable risk factors | Q48452477 | ||
| Daptomycin for eradication of a systemic infection with a methicillin-resistant-Staphylococcus aureus in a biventricular assist device recipient. | Q50971807 | ||
| Letter regarding article by Mauri et al, "Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison". | Q51305690 | ||
| Epidemiology of deep sternal wound infection in cardiac surgery. | Q51834647 | ||
| Postoperative mediastinitis in cardiac surgery - microbiology and pathogenesis. | Q65000546 | ||
| P433 | issue | 1 | |
| P921 | main subject | cardiac surgery | Q235007 |
| gram-positive bacteria | Q857288 | ||
| P304 | page(s) | 120 | |
| P577 | publication date | 2016-08-04 | |
| P1433 | published in | Journal of Cardiothoracic Surgery | Q2022384 |
| P1476 | title | Daptomycin for the treatment of major gram-positive infections after cardiac surgery | |
| P478 | volume | 11 |
| Q33788313 | Effectiveness and safety of daptomycin in patients with infective endocarditis undergoing heart valve replacement: a subgroup analysis from real-world data | cites work | P2860 |
Search more.